Links:
Links:
Despite updated gout management guidelines from European (EULAR) and British (BSR) societies, treatment of gout is suboptimal with regard to the use of urate-lowering therapy (ULT) and normalizing serum uric acid (< 6.0 mg/dl) levels.
A cohort analysis using UK gout patients (n =
Read Article
Links:
Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium.
Read Article
Urate lowering therapy (ULT) is the backbone therapy for long-term gout treatment and maintenance, but real-world gout management is often imperfect and suboptimal.
Read Article
Eric Dein @ericdeinmd( View Tweet )
Eric Dein @ericdeinmd( View Tweet )
David Liew @drdavidliew( View Tweet )
Eric Dein @ericdeinmd( View Tweet )
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.
Read Article
Links:
Links:
Links:
Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?
May 2022 EMA meeting the CHMP recommended new indications for
Links:
The cardiovascular (CV) risks of inflammation and gout are well known, but until recently hasn't been tied to calcium pyrophosphate deposition (CPPD) disease. A recent EHR study shows that acute CPPD crystal arthritis was significantly associated with elevated risks for non-fatal CV events.
Read Article
Links:
People with gout appeared less likely to develop dementia than age- and sex-matched peers, a database study from Korea found.
The analysis of more than 5,000 gout patients and 25,000 controls in Korea's national healthcare system yielded adjusted hazard ratios of 0.79 for overall new-
Read Article
Links:
